This dosing regimen is much higher than needed to inhibit HMG-CoA reductase (Van de Steeg et al., 2013), or the dose used for behavioral rescue in earlier studies of RASopathy mouse models (10 mg/kg, subcuteanous injection; Li et al., 2005; Lee et al., 2014; Schreiber et al., 2017). The gene discussed is HMGCR; the disease is RASopathy.